232 related articles for article (PubMed ID: 21356356)
1. Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
Gueugnon F; Leclercq S; Blanquart C; Sagan C; Cellerin L; Padieu M; Perigaud C; Scherpereel A; Gregoire M
Am J Pathol; 2011 Mar; 178(3):1033-42. PubMed ID: 21356356
[TBL] [Abstract][Full Text] [Related]
2. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
3. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
[TBL] [Abstract][Full Text] [Related]
4. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A
Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865
[TBL] [Abstract][Full Text] [Related]
5. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
6. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
7. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
Gee GV; Koestler DC; Christensen BC; Sugarbaker DJ; Ugolini D; Ivaldi GP; Resnick MB; Houseman EA; Kelsey KT; Marsit CJ
Int J Cancer; 2010 Dec; 127(12):2859-69. PubMed ID: 21351265
[TBL] [Abstract][Full Text] [Related]
8. Image cytometry: an aid for cytological diagnosis of pleural effusions.
Osterheld MC; Liette C; Anca M
Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
11. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
12. Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?
Mlika M; Ayadi-Kaddour A; Ksantini M; Bouraoui S; Mzabi S; El Mezni F
J Immunoassay Immunochem; 2013; 34(2):111-25. PubMed ID: 23537297
[TBL] [Abstract][Full Text] [Related]
13. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
Barbieri PG
Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233
[No Abstract] [Full Text] [Related]
14. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.
Emri S; Ustündağ Y; Budak T; Karakoca Y; Ozdemir O
Monaldi Arch Chest Dis; 1997 Aug; 52(4):335-8. PubMed ID: 9401361
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
[TBL] [Abstract][Full Text] [Related]
17. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
18. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
19. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
Porcel JM; Esquerda A; Rodriguez-Panadero F; Martínez-Iribarren A; Bielsa S
J Thorac Oncol; 2011 Jan; 6(1):190-4. PubMed ID: 21079519
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]